Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study
Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease
Paul Sekhri, seasoned life sciences executive with decades of drug development and extensive business development experience, appointed Chair of the Board of Directors
Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. The financing was led by Syncona Ltd. Alongside the financing, Resolution also announces the appointment of Paul Sekhri as Chair of the Board of Directors.
